Guidelines: Difference between revisions

From UrologySchool.com
Jump to navigation Jump to search
VisualWikitext
Created page with "== AUA == === Oncology === ==== Prostate ==== * Advanced Prostate Cancer (2020) * Adjuvant and Salvage Radiotherapy After Prostatectomy (2019) * Prostate Cancer Screening (2018) * Clinically Localized Prostate Cancer (2017) ==== Bladder ==== * Microscopic Hematuria (2020) * Muscle-invasive Bladder Cancer (2017) * Non-muscle Invasive Bladder Cancer (2016) ==== Kidney ==== * Renal Mass and Localized Renal Cancer (2021) ==== Testicular ==== * (2019) Included in Tes..."
 
 
(104 intermediate revisions by 3 users not shown)
Line 1: Line 1:
== AUA ==
== AUA Guidelines ==


=== Oncology ===
=== Oncology ===
Line 5: Line 5:
==== Prostate ====
==== Prostate ====


* Advanced Prostate Cancer (2020)
* '''<span style="color:#008000">NEW!</span>''' [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]
* Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]
* Prostate Cancer Screening (2018)
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]
* Clinically Localized Prostate Cancer (2017)
*[[AUA & ASTRO & SUO: Clinically Localized Prostate Cancer (2022)|Clinically Localized Prostate Cancer (2022)]]
*[[Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)]]
* [[AUA: Prostate Cancer Screening (2018)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2018)]]
* [[AUA: Clinically Localized Prostate Cancer (2017)|Clinically Localized Prostate Cancer (2017)]]


==== Bladder ====
==== Bladder ====


* Microscopic Hematuria (2020)
* '''<span style="color:#008000">NEW!</span>''' [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]]
* Muscle-invasive Bladder Cancer (2017)
*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]]
* Non-muscle Invasive Bladder Cancer (2016)
*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]]
*[[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2020)|Muscle-invasive Bladder Cancer (2020)]]
* [[Muscle-invasive Bladder Cancer (2017)]]
* [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]]


==== Kidney ====
==== Kidney ====


* Renal Mass and Localized Renal Cancer (2021)
* [[Renal Mass and Localized Renal Cancer (2021)]]


==== Testicular ====
==== Testicular ====


* (2019) Included in Testicular Tumours Chapter Notes  
* (2019) Included in [https://test.urologyschool.com/index.php/Germ_Cell_Tumours Testicular Tumours Chapter Notes]
 
==== Upper Tract Urothelial Carcinoma ====
* [[AUA: Upper Tract Urothelial Carcinoma (2023)|Upper Tract Urothelial Carcinoma (2023)]]


=== Non-oncology ===
=== Non-oncology ===
Line 28: Line 37:
==== Andrology ====
==== Andrology ====


* Testosterone Deficiency (2018)
* [[Priapism|Priapism (2021)]]
* Erectile Dysfunction (2018)
*[[Testosterone Deficiency (2018)]]
* Peyronie's Disease (2015)
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]]
* [[Peyronie's Disease (2015)]]


==== Functional ====
==== Functional ====


* Surgical Management BPH (2018)
* [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]
* AUA/CUA Mesh Position Statement (2019)
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
* Incontinence after Prostate Therapy (2019)
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]
* Female SUI (2017)
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]]
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]]
 
==== Infertility ====
 
* AUA/ASRM Infertility (2020) included in Chapter Notes of
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]]
** [[Infertility: Management|Management of Infertility]]


==== Infections and Inflammation ====
==== Infections and Inflammation ====


* AUA/CUA Recurrent UTI (2019)
* [[AUA & CUA Recurrent UTI (2019)|AUA/CUA Recurrent UTI (2019)]]
* Pediatrics Vesicoureteral Reflux (2017)
 
==== Pediatrics ====
*[[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]]
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]]


==== Stones ====
==== Stones ====


* Evaluation and Medical Management of Stones (2019)
* [[AUA: Evaluation and Medical Management of Stones (2019)|Evaluation and Medical Management of Stones (2019)]]
* Stone Surgery (2016)  
* [[AUA: Stone Surgery (2016)|Stone Surgery (2016)]]


==== Other ====
==== Other ====


* Urotrauma (2020)
* [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]
* Male Urethral Stricture (2016)
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]
* Vasectomy (2015)
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]]
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]
* [[AUA & CUA: Vasectomy (AUA 2015, CUA 2016)|Vasectomy (2015)]]


==== Contribute ====
==== Contribute ====


* BPH (2021)
* Overactive Bladder (2024)
* Infertility (2021)
*Incontinence after Prostate Therapy (2024 Amendment)
* Priapism (2021)
*Non-muscle Invasive Bladder Cancer (2024 Amendment)
* OAB (2019)
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
* Antibiotic Prophylaxis (2019)  
*Management of LUTS attributed to BPH (2023 Amendment)
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]
*Disorders of ejaculation (2020)
* Antibiotic Prophylaxis (2019)


== CUA ==
== CUA Guidelines ==


=== Oncology ===
=== Oncology ===
Prostate Castrate-resistant Prostate Cancer (2021)


Androgen Deprivation Therapy: Adverse Events & Management (2021)
==== Prostate ====


Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)
* [[CUA: Castrate-resistant Prostate Cancer (2021)|Castrate-resistant Prostate Cancer (2021)]]
* [[CUA: Androgen Deprivation Therapy: Adverse Events & Management (2021)|Androgen Deprivation Therapy: Adverse Events & Management (2021)]]
* [[CUA: Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)|Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)]]
* [[CUA: Testosterone Suppression (2018)|Testosterone Suppression (2018)]]
* [[CUA: Prostate Cancer Screening (2017)|Prostate Cancer Screening (2017)]]
* [[Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)]]
* [[CUA: Prostate Cancer Active Surveillance (2015)|Prostate Cancer Active Surveillance (2015)]]


Testosterone Suppression (2018)
==== Bladder ====


Prostate Cancer Screening (2017)
* [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2021)]]
* [[CUA: Advanced and Metastatic Urothelial Cancer (2019)|Advanced and Metastatic Urothelial Cancer (2019)]]
* [[CUA: Muscle-invasive Bladder Cancer (2019)|Muscle-invasive Bladder Cancer (2019)]]
* [[CUA: Asymptomatic Microscopic Hematuria (2008)|Asymptomatic Microscopic Hematuria (2008)]]


Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)
==== Kidney ====


Prostate Cancer Active Surveillance (2015)
* [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]]
* [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]]
* [[CUA: Small Renal Masses (2015)|Small Renal Masses (2015)]]
* [[CUA: Surgical Management of RCC (2014)|Surgical Management of RCC (2014)]]
* [[CUA: RCC Genetic Screening (2013)|RCC Genetic Screening (2013)]]


Bladder Non-muscle Invasive Bladder Cancer (2021)
=== Non-oncology ===


Advanced and Metastatic Urothelial Cancer (2019)
==== Andrology ====


Muscle-invasive Bladder Cancer (2019)
* [[CUA: Peyronie's Disease (2018)|Peyronie's Disease (2018)]]
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2021)]]


Asymptomatic Mircoscopic Hematuria (2008)
==== Functional ====


Kidney Follow-up Localized RCC (2018)
* [[CUA: Neurogenic Lower Urinary Tract Dysfunction (2019)|Neurogenic Lower Urinary Tract Dysfunction (2019)]]
* [[CUA: Male LUTS & BPH (2018)|Male LUTS/BPH (2018)]]
* [[AUA & CUA Mesh Position Statement (2019)|CUA/AUA Mesh Position Statement (2019)]]
* [[CUA: Overactive Bladder (2017)|Overactive Bladder (2017)]]


Cystic Renal Lesions (2017)
==== Infections and Inflammation ====


Small Renal Masses (2015)
* [[AUA & CUA Recurrent UTI (2019)|CUA/AUA Recurrent UTI (2019)]]
* [[CUA: Antibiotic Prophylaxis (2015)|Antibiotic Prophylaxis (2015)]]
* [[CUA: Chronic Scrotal Pain (2018)|Chronic Scrotal Pain (2018)]]
* [[CUA: Interstitial Cystitis (2016)|Interstitial Cystitis (2016)]]


Surgical Management of RCC (2014)
==== Infertility ====


RCC Genetic Screening (2013)
* [[CUA: Azoospermia (2015)|Azoospermia (2015)]]


Non-oncology
==== Pediatrics ====


Andrology Peyronie's Disease (2018)
* [[CUA: Circumcision (2018)|Circumcision (2018)]]
* [[CUA: Antenatal hydronephrosis (2017)|Antenatal hydronephrosis (2017)]]
* [[CUA: Cryptorchidism (2017)|Cryptorchidism (2017)]]
* [[CUA: Multicystic Dysplastic Kidney in the Neonate (2015)|Multicystic Dysplastic Kidney in the Neonate (2015)]]


Erectile Dysfunction (2021)
==== Stones ====


Functional Neurogenic Lower Urinary Tract Dysfunction (2019)
* [[CUA: Evaluation and Medical Management of Stones (2016)|Evaluation and Medical Management of Stones (2016)]]
* [[CUA: Ureteral Calculi (2015)|Ureteral Calculi (2015)]]


Male LUTS/BPH (2018)
==== Other ====


CUA/AUA Mesh Position Statement (2019)
* [[AUA & CUA: Vasectomy (AUA 2015, CUA 2022)|Vasectomy (2022)]]
* [[CUA: Adrenal Mass (2011)|Adrenal Mass (2011)]]
* [[CUA: Radiation-induced Hemorrhagic Cystitis (2018)|Radiation-induced Hemorrhagic Cystitis (2018)]]
* [[CUA: VTE Prophylaxis (2019)|VTE Prophylaxis (2019)]]
*[[CUA: Vasectomy (2016)|Vasectomy (2016)]]


Overactive Bladder (2017)
==== Contribute ====
 
Infections and Inflammation CUA/AUA Recurrent UTI (2019)
 
Antibiotic Prophylaxis (2015)
 
Chronic Scrotal Pain (2018)
 
Interstitial Cystitis (2016)
 
Infertility Azoospermia (2015)
 
Pediatrics Circumcision (2018)
 
Antenatal hydronephrosis (2017)
 
Cryptorchidism (2017)
 
Multicystic Dysplastic Kidney in the Neonate (2015)
 
Stones Evaluation and Medical Management of Stones (2016)
 
Ureteral Calculi (2015)
 
Other Vasectomy (2016)
 
Adrenal Mass (2011)
 
Radiation-induced Hemorrhagic Cystitis (2018)
 
VTE Prophylaxis (2019)
 
Contribute
 
Ureteral calculi (2022)
 
Pediatric bladder dysfunction (2021)
 
Sporadic angiomyolipomas (2020)
 
Male urethral stricture (2020)
 
Catheter use (2020)


Renal mass biopsy (2019)
*Ureteral calculi (2022)
* Pediatric bladder dysfunction (2021)
* Sporadic angiomyolipomas (2020)
* Male urethral stricture (2020)
* Catheter use (2020)
* Renal mass biopsy (2019)
* Pheochromocytoma surveillance (2019)
* Pediatric hemorrhagic cystitis (2019)


Pheochromocytoma surveillance (2019)
== Other Guidelines ==


Pediatric hemorrhagic cystitis (2019)
=== '''<span style="color:#008000">NEW!</span>''' [[EAU & ASCO: Penile Cancer 2023|Penile Cancer (EAU/ASCO 2023)]] ===

Latest revision as of 18:35, 19 September 2024

AUA Guidelines[edit | edit source]

Oncology[edit | edit source]

Prostate[edit | edit source]

Bladder[edit | edit source]

Kidney[edit | edit source]

Testicular[edit | edit source]

Upper Tract Urothelial Carcinoma[edit | edit source]

Non-oncology[edit | edit source]

Andrology[edit | edit source]

Functional[edit | edit source]

Infertility[edit | edit source]

Infections and Inflammation[edit | edit source]

Pediatrics[edit | edit source]

Stones[edit | edit source]

Other[edit | edit source]

Contribute[edit | edit source]

  • Overactive Bladder (2024)
  • Incontinence after Prostate Therapy (2024 Amendment)
  • Non-muscle Invasive Bladder Cancer (2024 Amendment)
  • Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
  • Management of LUTS attributed to BPH (2023 Amendment)
  • Neurogenic LUTD (2021)
  • Disorders of ejaculation (2020)
  • Antibiotic Prophylaxis (2019)

CUA Guidelines[edit | edit source]

Oncology[edit | edit source]

Prostate[edit | edit source]

Bladder[edit | edit source]

Kidney[edit | edit source]

Non-oncology[edit | edit source]

Andrology[edit | edit source]

Functional[edit | edit source]

Infections and Inflammation[edit | edit source]

Infertility[edit | edit source]

Pediatrics[edit | edit source]

Stones[edit | edit source]

Other[edit | edit source]

Contribute[edit | edit source]

  • Ureteral calculi (2022)
  • Pediatric bladder dysfunction (2021)
  • Sporadic angiomyolipomas (2020)
  • Male urethral stricture (2020)
  • Catheter use (2020)
  • Renal mass biopsy (2019)
  • Pheochromocytoma surveillance (2019)
  • Pediatric hemorrhagic cystitis (2019)

Other Guidelines[edit | edit source]

NEW! Penile Cancer (EAU/ASCO 2023)[edit | edit source]

Retrieved from "https://urologyschool.com/wikiuro/index.php?title=Guidelines&oldid=6940"